Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan

Andrew H Ko
Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA

Abstract: Nanoliposomal irinotecan (nal-IRI) was originally developed using an efficient and high-loading capacity system to encapsulate irinotecan within a liposomal carrier, producing a therapeutic agent with improved biodistribution and pharmacokinetic characteristics compared to free drug. Specifically, administration of nal-IRI results in prolonged exposure of SN-38, the active metabolite of irinotecan, within tumors, while at the same time offering the advantage of less systemic toxicity than traditional irinotecan. These favorable properties of nal-IRI, confirmed in a variety of tumor xenograft models, led to its clinical evaluation in a number of disease indications for which camptothecins have proven activity, including in colorectal, gastric, and pancreatic cancers. The culmination of these clinical trials was the NAPOLI-1 (Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy) trial, an international Phase III study evaluating nal-IRI both alone and in combination with 5-fluorouracil and leucovorin in patients with metastatic pancreatic adenocarcinoma following progression on gemcitabine-based chemotherapy. Positive results from NAPOLI-1 led to approval of nal-IRI (with 5-fluorouracil/leucovorin) in October 2015 by the US Food and Drug Administration specifically for the treatment of metastatic pancreatic cancer in the second-line setting and beyond, a clinical context in which there had previously been no accepted standard of care. As such, nal-IRI represents an important landmark in cancer drug development, and potentially ushered in a new era where a greater number of patients with advanced pancreatic cancer can be sequenced through multiple lines of therapy translating into meaningful improvements in survival.

Keywords: pancreatic cancer, irinotecan, nanoliposomal, clinical trial, NAPOLI-1

Introduction

Pancreatic cancer currently represents the fourth leading cause of cancer-related mortality in the United States among both males and females, with an estimated 48,960 new cases and 40,560 deaths attributed to this malignancy in 2015. Moreover, the number of pancreatic cancer-related deaths continues to increase, with current projections indicating it will likely rise to the second-leading cause of cancer-related mortality in the United States sometime during the next decade, trailing only lung cancer. Globally, pancreatic cancer ranks as the seventh most common cause of cancer death, responsible for more than 330,000 deaths worldwide as of 2012 (4% of the total).

These statistical findings reflect the sobering realities of this disease: the vast majority of patients present at advanced stages of disease beyond which a potentially curative operation is feasible; and therapeutic gains in this disease have been more modest rather than transformative over the past several decades. Moreover, while our understanding of the fundamental pathogenic and molecular bases of pancreatic
cancer continues to grow, an ability to translate these findings into “actionable” results has been limited, and we still lack useful predictive biomarkers that can aid in decision-making and bring our treatment paradigms into the modern realm of precision medicine.

On a more positive note, over the past several years we have seen positive results from multiple Phase III clinical trials that have expanded our therapeutic options for patients with advanced pancreatic cancer. The most recent of these developments has led to the approval by the US Food and Drug Administration (FDA) of nanoliposomal irinotecan (herein referred to as nal-IRI) in October 2015. This represents a significant milestone as this drug represents the first agent specifically approved for use in the second-line treatment of metastatic pancreatic cancer.

This paper will start by reviewing briefly the current treatment landscape for pancreatic cancer, with special attention on the proven therapeutic options (or, more accurately, lack thereof) that exist beyond frontline chemotherapy, as this is the specific indication for which nanoliposomal irinotecan has been approved. This will be followed by a discussion of the preclinical development of nal-IRI and its pharmacologic properties; and finally clinical evaluation of nal-IRI from early dose-finding studies to disease-specific clinical trials, with a particular focus on the development and approval of this novel agent in pancreatic cancer.

The current treatment landscape for metastatic pancreatic cancer
Chemotherapy remains the mainstay of treatment for patients diagnosed with metastatic pancreatic cancer. Single-agent gemcitabine became the standard of care back in the mid-1990s following results of a Phase III study that demonstrated improvements in overall survival (OS), response rate, as well as a quality of life measure termed clinical benefit response (a composite measure of analgesic requirements, performance status, and change in weight) when compared with 5-fluorouracil (5-FU). Over the subsequent decade plus, a number of Phase III trials were designed to assess whether any survival benefit could be derived from adding additional cytotoxic or targeted agents to gemcitabine. With the exception of the PA.3 trial, which evaluated erlotinib, an oral tyrosine kinase inhibitor that binds to the epidermal growth factor receptor (EGFR), none of these studies demonstrated a statistically significant survival advantage of combination therapy when compared to gemcitabine alone. Moreover, despite approval of erlotinib by the FDA in 2005, its use has not been very widespread, based on a fairly modest incremental survival benefit when added to gemcitabine (hazard ratio (HR) of 0.81 for overall survival) and substantial toxicities.

After this relatively fallow period through the early 2000s, positive data from a couple of randomized Phase III trials over the past several years have led to the acceptance of two new standards of care for the first-line treatment of metastatic pancreatic cancer. PRODIGE 4/ACCORD 11 was a 342-patient French trial in which FOLFIRINOX, a multi-drug combination consisting of bolus plus infusional 5-FU, leucovorin (LV), irinotecan, and oxaliplatin administered on a biweekly dosing schedule, was compared to single-agent gemcitabine in patients with previously untreated metastatic pancreatic cancer and intact functional status (Eastern Cooperative Oncology Group performance status of 0–1). This study unequivocally demonstrated the superiority of FOLFIRINOX in terms of all clinically relevant parameters, including prolongation of overall survival (median OS: 11.1 vs 6.8 months, HR of 0.57; P<0.001) and progression-free survival, higher objective response rate, and longer preservation of quality of life. As a result, FOLFIRINOX has become the preferred first-line choice for select patients who are robust enough to tolerate this somewhat more aggressive chemotherapy regimen.

A second chemotherapy platform now in widespread use for metastatic pancreatic cancer consists of the combination of gemcitabine plus nab-paclitaxel (Celgene, Summit, NJ, USA), a 130-nm albumin-bound formulation of paclitaxel particles. Nab-paclitaxel, originally FDA-approved for advanced breast cancer back in 2005, was developed in part to eliminate the allergic reactions that could occur from polyoxethylated castor oil (Cremphor EL; BASF, Ludwigshafen, Germany), a vehicle needed for parenteral administration of free paclitaxel. Its subsequent evaluation in pancreatic cancer was based in part on molecular profiling of pancreatic tumor samples, in which overexpression of the SPARC protein (secreted protein acidic and rich in cysteine), an albumin-binding protein, was observed. Following promising results from a Phase I/II trial of gemcitabine plus nab-paclitaxel, an international Phase III study (the MPACT trial) was conducted in which 861 patients with metastatic pancreatic cancer were randomized to receive gemcitabine either alone or in combination with nab-paclitaxel. Patients receiving the doublet had superior outcomes, including a significant prolongation of survival (median OS: 8.5 vs 6.7 months, HR =0.72; P<0.001), thus leading to FDA approval of nab-paclitaxel for this indication in 2014.
What options do we currently have beyond frontline chemotherapy?
Data from contemporary pancreatic cancer trials suggest that fewer than half of patients receiving first-line chemotherapy go on to receive any additional therapy; for example, in the aforementioned MPACT trial, only 40% of patients received second-line treatment. This reflects both the often rapid clinical deterioration of patients at this stage of their disease trajectory as well as the lack of available therapeutic options in the salvage setting. The emergence of two frontline standards for metastatic pancreatic cancer may now afford greater opportunity to sequence patients across multiple lines of therapy. It is important, however, to recognize that randomized clinical trial data supporting a sequential approach of FOLFRINOX (FOLFIRINOX regime consisting of folinic acid, 5-FU, leucovorin, oxaliplatin) followed by gemcitabine/nab-paclitaxel (or the reverse) are still lacking, with only small series (primarily retrospective) and case reports suggesting modest efficacy of each of these regimens in the second-line setting.

A variety of other therapies, including not only classical cytotoxic drugs (alone and in combination) but also molecularly targeted agents and, more recently, immunotherapies, have been investigated in this salvage setting. One systematic review published in 2013 evaluating 34 clinical trials of different second-line regimens following gemcitabine-based therapy concluded that continuing with some form of therapy after progression on first-line treatment did confer a survival advantage when compared to best supportive care, thus supporting this strategy as a general principle. However, the challenges of interpreting this mix of studies include small sample sizes, nonrandomized trial design for the majority with resultant selection bias, and sometimes conflicting results. For example, the de facto standard of care for many years when treating patients with gemcitabine-resistant pancreatic cancer was to move next to a combination of a platinum analog plus a fluoropyrimidine. This approach was informed in large part by results from one of the largest randomized studies (a German trial called CONKO-003) in this disease setting demonstrating a survival advantage of OFF (oxaliplatin, folic acid, and fluorouracil) compared to FF alone (median OS: 5.9 vs 3.3 months, HR =0.66; log-rank P=0.010). Conversely, a later trial conducted in Canada called PANCREOX showed almost the precise opposite results in a similar patient population, with patients treated with FOLFOX (chemotherapy regimen of folic acid, 5-FU, and oxaliplatin) faring no better – and possibly worse – than those receiving 5-FU/LV alone.

In addition to nal-IRI, several other novel agents have shown promising results in the second-line (and beyond) setting for metastatic pancreatic cancer and are moving ahead in clinical development. In the randomized Phase II RECAP trial, the JAK 1/2 inhibitor ruxolitinib (Jakafi, Incyte Pharmaceuticals, New York, NY, USA) was evaluated in combination with capecitabine in patients who had failed gemcitabine-based chemotherapy. In a preplanned analysis of the subgroup of patients with elevated levels of C-reactive protein (CRP) (an indicator of high levels of systemic inflammation that contributes to cancer-related cachexia), median survival was significantly longer in those patients who received the ruxolitinib/capecitabine combination compared to capecitabine alone (83 vs 55 days, HR =0.47; P=0.01). These results have led to two Phase III trials (JANUS 1 and JANUS 2) that are currently underway to evaluate ruxolitinib specifically in gemcitabine-refractory pancreatic cancer patients with high CRP levels. A second, immune-based approach being tested in this setting is CRS-207 (Aduro Biosciences, Berkeley, CA, USA), a live-attenuated Listeria monocytogenes vaccine vector genetically engineered to express the tumor-associated antigen, mesothelin. Immunotherapeutic strategies have not produced as dramatic results in pancreatic cancer when compared with other solid malignancies, perhaps due to pancreatic cancer being generally considered a more immune-privileged tumor. Nevertheless, in a randomized Phase II trial in patients with chemorefractory metastatic pancreatic cancer, CRS-207, when combined with the cellular vaccine GVAX, significantly improved survival when compared to GVAX alone (median OS: 6.0 vs 3.4 months, HR =0.4477; P=0.0057), including in some patients with very prolonged disease stabilizations.

Introduction to nal-IRI: initial drug development
Liposomes are spherical drug carrier vehicles with a bilayer lipid membrane, typically ranging in size anywhere from approximately 40 nm to several microns. The theoretical benefits of developing liposomal formulations of anticancer drugs, including both traditional chemotherapy agents as well as molecularly targeted therapies (such as small molecule inhibitors), are well-established; these include the possibility of encapsulating poorly soluble drugs, protecting therapeutic agents from premature clearance and metabolism, and improving biodistribution and pharmacokinetics via slow release of the parent agent (reviewed in Bertrand...
et al\textsuperscript{24}), resulting in simultaneously greater potency and decreased side effects. Ideally, liposomes should retain encapsulated drug in circulation and then release the drug in a time-controlled fashion after arrival at the target tissue. This release rate is an important factor in drug potency that can be controlled, to some extent, by various physiochemical properties of the liposome, including both lipid and interior buffer composition.\textsuperscript{25}

It is believed that nanoliposomes accumulate preferentially in the tumor through a phenomenon known as the enhanced permeability and retention (EPR) effect.\textsuperscript{26} This EPR effect describes the combination of irregular, permeable tumor blood vessels with large fenestrations that enable extravasation of macromolecules (such as liposomes), together with impaired lymphatic drainage. These findings in concert lead to increased cumulative trapping of liposomal drug in the tumor microenvironment, relative to other tissues, in what could be characterized as a form of passive targeting. Once deposited in the tumor, the liposomal agent can then be taken up by tumor-resident macrophages, which release the bound drug resulting in high intratumoral levels of active drug.\textsuperscript{27} The final result is improved pharmacological potency of the liposomal formulation compared to the same drug administered in free form.

At the same time, some technical challenges persist in liposomal technology, including the efficient loading of cancer drugs at high drug-to-lipid ratios, and preventing phagocytosis of liposome–plasma protein complexes by the reticuloendothelial system. Newer stealth technologies, such as the incorporation of polyethylene glycol (PEG) to the liposome surface, are being applied to prevent binding of liposomes by circulating plasma proteins with the goal of decreasing elimination from the circulation.

The therapeutic efficacy of liposomal agents in oncology has been established in routine clinical practice, with agents such as liposome-encapsulated doxorubicin currently being used for a variety of malignant indications (Kaposi sarcoma, multiple myeloma, ovarian cancer), offering the advantage of decreased cardiac toxicity of the cytotoxic drug. However, specific to pancreatic cancer, only a small number of liposomally formulated agents have been tested in the clinical setting, with none gaining significant traction.

A larger randomized Phase II trial evaluating a novel cationic liposomal formulation of paclitaxel (EndoTAG-1) in combination with gemcitabine as first-line treatment for patients with advanced pancreatic cancer showed somewhat greater promise.\textsuperscript{29} The investigators reported (in abstract form only) a survival benefit with the addition of EndoTAG-1 to gemcitabine, with an HR for overall survival of 0.67 when the highest dose level of this agent was administered together with gemcitabine compared to gemcitabine alone. Nevertheless, neither of these liposomal agents went on to further clinical development in pancreatic cancer.

nal-IRI (originally referred to as PEP-02 when licensing rights were owned by PharmaEngine [Taipei, Taiwan]; subsequently relicensed as MM-398 [Merrimack Pharmaceuticals, Cambridge, MA, USA]), represents a novel nanoliposomal formulation of irinotecan hydrochloride, a semisynthetic analog of the natural alkaloid camptothecin currently used in the treatment of a wide variety of malignancies, including colorectal, gastroesophageal, small cell lung, and breast cancer. Irinotecan, by stabilizing the complex between topoisomerase I (TOP1) and bound DNA, induces stalling of replication forks, ultimately leading to DNA strand breaks and inhibition of replication. Time of drug exposure is an important driver for its cytotoxic effects,\textsuperscript{30} suggesting that irinotecan and other TOP1-targeting agents, in liposomal form, would be able to take particular advantage of the EPR effect with preferential intratumoral accumulation and exposure.

The dose-limiting toxicities (DLTs) of irinotecan are well-described, most notably diarrhea (which can be severe) and cytopenias. nal-IRI was designed in part to reduce the incidence and severity of these toxicities while maintaining or increasing the antitumor activity of the parent drug, offering an improved therapeutic window. Specifically, the liposomal carrier system offers a way to protect irinotecan from premature conversion by nonspecific carboxylesterases into its active metabolite, SN-38, which is about 100- to 1,000-fold more potent.\textsuperscript{31} This produces lower maximum plasma concentration ($C_{\text{max}}$) and consequently reduced drug toxicity, even while lower drug elimination prolongs systemic circulation of the liposomal construct. Despite these theoretical advantages, prior liposomal formulations of irinotecan, as well as of other camptothecins (lurtotecan and SN-38, among others), have not necessarily shown improved pharmacokinetic characteristics or toxicity profiles compared to their free drug counterparts when evaluated in the preclinical setting.\textsuperscript{32–34}
The development of nal-IRI was originally described in 2006 by Drummond et al,35 who used a novel intraliposomal drug stabilization technique to load irinotecan into a nanoparticle/liposome construct in efficient manner. Specifically, a polyalkylammonium salt of a nonpolymeric (sucrose octasulfate) highly charged multivalent anion was employed as an intraliposomal trapping agent, resulting in formation of intraliposomal drug–polyanion complexes. (A polymeric agent, polyphosphate, was also tested for synthesis of this drug; but the superior results of sucrose octasulfate led to this being the choice for subsequent clinical development). The triethylammonium component of the salt ensures the charge neutrality of the liposome interior by simultaneous efflux of cations accompanying the influx of the drug, and possibly even formation of a self-perpetuating pH gradient to drive progressive drug accumulation. This may help explain the remarkably high loading capacity of triethylammonium sucrose octasulfate liposomes, with 800 g of irinotecan per mole of phospholipid (corresponding to 109,000 drug molecules per particle).

### Preclinical evaluation of nal-IRI

Pharmacokinetic testing of nal-IRI in normal female rats demonstrated high in vivo stability of the liposomal construct, with significantly longer circulation times when compared to administration of free drug (half-life \( t_{1/2} \) = 10.7 hours compared to 0.27 hours, respectively).35 Almost one-quarter (23.2%) of the injected dose of nal-IRI was detectable in circulation at 24 hours, compared to free CPT-11 (irinotecan), of which 98% is cleared within 30 minutes. Moreover, with the nal-IRI formulation there was less premature conversion to SN-38, due in part to slow release of irinotecan from liposomes \( t_{1/2} \) for irinotecan release = 56.8 hours). When tested in mice, nal-IRI showed dramatic regressions in a breast (BT474) tumor xenograft model with a 100% cure rate, without significant corresponding treatment-related toxicities aside from transient weight loss. Antitumor activity in a colon cancer (HT29) xenograft model was also observed, albeit not quite to as striking a degree.

Hann et al36 were the first to evaluate nal-IRI in pancreatic cancer, in the context of a bioluminescent-based orthotopic xenograft model (COLO357/L3.6pl). Compared to the equivalent dose of free drug, nal-IRI (as well as a separate, novel EGFR-targeted immunoliposomal form of irinotecan) showed superior antitumor activity, including a number of durable tumor regressions, without any significant systemic toxicity.

In a more recently published study, Kalra et al37 measured irinotecan and SN-38 levels in both plasma and tumor in mice harboring a variety of cell-line and patient-derived tumor xenografts (colorectal, ovarian, lung, and pancreatic) following administration of either nal-IRI or free irinotecan. Consistent with prior findings, plasma levels of both irinotecan and SN-38 persisted much longer in circulation (>50 hours) following administration of nal-IRI compared to free irinotecan. Similarly, prolonged exposure within tumors of both irinotecan and SN-38 was observed following nal-IRI administration; levels of both were still detectable at 168 hours, far longer than free irinotecan, where tumoral clearance of drug and active metabolite was noted by 24–48 hours. Ultimately, using model sensitivity analyses, these investigators determined that tumor SN-38 duration – reflecting both drug deposition and local activation of irinotecan by carboxylesterases to its active metabolite – represents the key driver of in vivo sensitivity to irinotecan-based treatment. Hence, the superior antitumor activity of nal-IRI could be attributed to its superior pharmacokinetic properties, with the ability of this liposomal construct to prolong drug exposure within tumors, compared to free irinotecan.

### Clinical development of nal-IRI

The first-in-human clinical trial of nal-IRI, conducted in Taiwan by Chang et al,38 consisted of a Phase I dose-escalation study in patients with advanced refractory solid tumors, including cervical, breast, neuroendocrine, pancreatic, non-small-cell lung, and thymic cancers. In total, eleven patients were enrolled across three dose levels, with the maximal tolerated dose (MTD) established at 120 mg/m² on an every-3-week schedule. DLTs at the next higher dose level (180 mg/m²) included grade 4 neutropenia in one patient and grade 4 febrile neutropenia, grade 4 thrombocytopenia with bleeding, and grade 4 diarrhea in a second patient resulting in death from septicemia and disseminated intravascular coagulation. Pharmacokinetic analyses demonstrated slow clearance, small volume of distribution, and prolonged terminal half-life of nal-IRI – all findings consistent with preclinical PK studies of nal-IRI in mice and rats – with a plasma concentration-time profile approximately matching that of total irinotecan, reflecting the slow release of free-form irinotecan from the nanopelosomal carrier over time. The area under the curve of SN-38 at MTD of nal-IRI was comparable to historic data for conventional irinotecan dosed at 300–350 mg/m². Of the six patients enrolled at MTD, gastrointestinal toxicities were frequently observed, including grade 3/4 diarrhea in two patients.
(33.3%) and grade 3/4 vomiting in four patients (66.7%). Two of ten (20%) response-evaluable patients demonstrated a partial response by RECIST (Response Evaluation Criteria in Solid Tumors); notably, this included the one patient with pancreatic cancer treated at 180 mg/m² who had failed several prior lines of chemotherapy.

A number of Phase I, II, and III clinical trials of nal-IRI have since been conducted across a variety of solid tumors, with a particular focus on those disease indications in which irinotecan has demonstrable clinical activity. A summary of these studies is listed in Table 1. Chen et al²⁸ were the first to report (in abstract form) the feasibility of combining nal-IRI with a second chemotherapeutic agent, 5-FU, in a dose-finding Phase I trial in patients with heavily pretreated solid tumors. The MTD using an every-3-week dosing schedule consisted of nal-IRI 80 mg/m² (day 1) plus 24-hour infusional 5-FU 2,000 mg/m² and LV 200 mg/m² (days 1 and 8). DLTs at higher doses of nal-IRI included diarrhea and cytopenias. The best response of 15 evaluable patients was partial response in two patients (gastric cancer and breast cancer) and stable disease in an additional nine.

Table 1 Completed and ongoing clinical studies of nal-IRI

<table>
<thead>
<tr>
<th>Indication</th>
<th>Regimen</th>
<th>Phase</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advanced solid tumors</td>
<td>nal-IRI q3 weeks</td>
<td>I</td>
<td>Chang et al³⁸</td>
</tr>
<tr>
<td>Advanced solid tumors</td>
<td>nal-IRI (day 1) plus infusional 5-FU/LV (days 1 and 8) q3 weeks</td>
<td>I</td>
<td>Chen et al²⁹</td>
</tr>
<tr>
<td>Recurrent high-grade glioma</td>
<td>nal-IRI q3 weeks</td>
<td>I</td>
<td>Clarke et al⁴⁰</td>
</tr>
<tr>
<td>Pediatric solid tumors</td>
<td>nal-IRI plus cyclophosphamide (dosing schedule not specified) q3 weeks</td>
<td>I</td>
<td>NCT02013336</td>
</tr>
<tr>
<td>Metastatic colorectal cancer, following first-line oxaliplatin-based chemotherapy</td>
<td>nal-IRI q2 weeks</td>
<td>II</td>
<td>Chen et al⁴⁰</td>
</tr>
<tr>
<td>Metastatic pancreatic cancer, gemcitabine-refractory</td>
<td>nal-IRI q3 weeks</td>
<td>II</td>
<td>Ko et al⁴⁵</td>
</tr>
<tr>
<td>Metastatic gastric cancer, following first-line chemotherapy</td>
<td>nal-IRI q3 weeks (comparator arms: irinotecan, docetaxel)</td>
<td>II (3-arm randomization)</td>
<td>Roy et al⁴²</td>
</tr>
<tr>
<td>Metastatic colorectal cancer, following first-line oxaliplatin-based chemotherapy</td>
<td>nal-IRI plus 5-FU/LV q2 weeks (comparator arm: FOLFIRI)</td>
<td>II (2-arm randomization)</td>
<td>Chibaudel et al⁴¹</td>
</tr>
<tr>
<td>Metastatic pancreatic cancer, untreated</td>
<td>nal-IRI plus oxaliplatin and infusional 5-FU/LV q2 weeks (comparator arms: FOLFOX, gemcitabine/nab-paclitaxel)</td>
<td>II (3-arm randomization)</td>
<td>NCT02551991³¹</td>
</tr>
<tr>
<td>Metastatic pancreatic cancer, gemcitabine-refractory</td>
<td>nal-IRI q3 weeks</td>
<td>III</td>
<td>von Hoff et al⁴⁶</td>
</tr>
<tr>
<td></td>
<td>nal-IRI plus 5-FU/LV q2 weeks (comparator arm: 5-FU/LV)</td>
<td></td>
<td>Chen et al⁴⁷</td>
</tr>
</tbody>
</table>

Note: Trial ongoing

Abbreviations: q3, every 3 weeks; q2, every 2 weeks; nal-IRI, nanoliposomal irinotecan; 5-FU, 5-fluorouracil; LV, leucovorin; FOLFIRI, 5-FU/LV plus irinotecan; FOLFOX, 5-FU/LV plus oxaliplatin.
which single-agent irinotecan represents one of the standards of care. Patients were randomized in 1:1:1 fashion to receive nal-IRI, irinotecan, or docetaxel (n=44 in each arm). Objective response rate, which represented the primary study endpoint, was similar for nal-IRI (13.6%) and docetaxel (15.9%), both of which were higher than for irinotecan (6.8%). Median progression-free and overall survival rates were similar across all three arms. This study was also informative in allowing the opportunity to directly compare the toxicity profile of nal-IRI (dosed at 120 mg/m² in this trial) with that of standard irinotecan (300 mg/m²). Rates of grade 3–4 adverse events were similar between these two treatment arms (38.6% vs 34.1%), as was diarrhea of any grade (72.7% vs 68.2%). Additionally, similar to prior preclinical and clinical studies, nal-IRI also demonstrated favorable pharmacokinetic properties, including a larger area under the curve, lower clearance, and smaller volume of distribution for total irinotecan when compared to free irinotecan. A summary comparing the major pharmacokinetic properties of nal-IRI and free irinotecan is provided in Table 2.

### Table 2: Comparison of pharmacokinetic properties of nal-IRI vs free irinotecan

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Free irinotecan</th>
<th>Nanoliposomal irinotecan</th>
</tr>
</thead>
<tbody>
<tr>
<td>C max (ng/mL)</td>
<td>4.265</td>
<td>60.842</td>
</tr>
<tr>
<td>T max (hours)</td>
<td>1.6</td>
<td>2.1</td>
</tr>
<tr>
<td>AUC 0−∞ (hr-ng/mL)</td>
<td>24,155</td>
<td>1,651,508</td>
</tr>
<tr>
<td>AUC 0−t (hr-ng/mL)</td>
<td>26,159</td>
<td>1,812,221</td>
</tr>
<tr>
<td>CL (mL/hr/m²)</td>
<td>12,886</td>
<td>191</td>
</tr>
<tr>
<td>t 1/2 (hours)</td>
<td>7.7</td>
<td>21.2</td>
</tr>
</tbody>
</table>

**Notes:** Adapted from Roy AC, Park SR, Cunningham D, et al. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol. 2013;24(6):1567–1573.42 By permission of Oxford University Press on behalf the European Society for Medical Oncology.

**Abbreviations:** nal-IRI, nanoliposomal irinotecan; C max, peak plasma concentration; T max, time to reach C max; AUC, area under the curve; CL, clearance; t 1/2, elimination half-life.

### Nal-IRI in pancreatic cancer

The track record of irinotecan in pancreatic cancer clinical trials has a somewhat checkered past. As noted earlier, irinotecan comprises a key component of the FOLFIRINOX regimen that now represents a gold standard in the frontline setting. Conversely, in two randomized Phase III trials for metastatic pancreatic cancer, the addition of irinotecan to gemcitabine did not confer any survival benefit.43,44 Other smaller Phase II trials evaluating irinotecan alone and in combination with other agents, in particular fluoropyrimidines, have demonstrated modest activity in pancreatic cancer, most commonly in the postgemcitabine setting (Table 3).

Ko et al45 conducted the first pancreas-specific trial of nal-IRI, consisting of a multinational Phase II study in patients with metastatic pancreatic cancer who had progressed on frontline gemcitabine-based chemotherapy. For this single-arm trial, conducted in the United States and Taiwan, forty patients received single-agent nal-IRI on an every 3-week schedule. Starting doses were 120 mg/m², with the option of dose-escalating to 150 mg/m² if the first cycle was well-tolerated. Overall, 26 patients (65%) experienced at least one treatment-emergent adverse event categorized as grade 3 or higher by National Cancer Institute Common Toxicity Criteria (NCI-CTC) criteria. Most frequent grade 3–5 toxicities included neutropenia (30%), fatigue/asthenia (20%), diarrhea (15%), nausea (10%), and anorexia (10%). Also of particular note was three patients (7.5%) who died related to complications of treatment, including aspiration pneumonia, sepsis, and respiratory failure, all developed in the setting of neutropenia. In terms of efficacy, three patients achieved a partial response as evaluated by RECIST criteria, with an additional 17 (42.5%) demonstrating stable disease for a minimum of two cycles. Ten patients (31.3%) experienced a CA19-9 response, defined as a decline in this tumor marker by 50% or greater for those with baseline levels greater than two times the upper limit of normal.

### Table 3: Select studies of irinotecan, alone or in combination with a fluoropyrimidine, in advanced pancreatic cancer

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Sample size</th>
<th>RR (%)</th>
<th>PFS/TTP (months)</th>
<th>Median survival (months)</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Irinotecan</td>
<td>33</td>
<td>9</td>
<td>2.0</td>
<td>6.6</td>
<td>Yi et al40</td>
</tr>
<tr>
<td>Irinotecan</td>
<td>56</td>
<td>3.6</td>
<td>2.9</td>
<td>5.3</td>
<td>Takahara et al41</td>
</tr>
<tr>
<td>FOLFIRI</td>
<td>40</td>
<td>37.5</td>
<td>5.6</td>
<td>12.1</td>
<td>Taieb et al42</td>
</tr>
<tr>
<td>FOLFIRI</td>
<td>31</td>
<td>0</td>
<td>1.9</td>
<td>3.9</td>
<td>Yoo et al43</td>
</tr>
<tr>
<td>FOLFIRI</td>
<td>40</td>
<td>15</td>
<td>3.7</td>
<td>6.0</td>
<td>Gebbia et al44</td>
</tr>
<tr>
<td>FOLFIRI or XELIRI</td>
<td>34</td>
<td>0</td>
<td>2.0</td>
<td>4.2</td>
<td>Cereda et al45</td>
</tr>
<tr>
<td>FOLFIRI</td>
<td>50</td>
<td>8.0</td>
<td>3.2</td>
<td>5.0</td>
<td>Zaniboni et al46</td>
</tr>
<tr>
<td>FOLFIRI</td>
<td>63</td>
<td>7.9</td>
<td>3.0</td>
<td>6.6</td>
<td>Neuzillet et al47</td>
</tr>
<tr>
<td>Irinotecan plus S-1</td>
<td>60</td>
<td>18</td>
<td>3.6</td>
<td>6.9</td>
<td>Mizuno et al48</td>
</tr>
</tbody>
</table>

**Notes:** Evaluated in first-line setting; all other studies were conducted in previously treated patients.

**Abbreviations:** RR, relative risk; PFS, progression-free survival; TTP, time to progression; FOLFIRI, 5-FU/LV plus irinotecan; nal-IRI, nanoliposomal irinotecan; S-FLI, S-fluorouracil/LV, leucovorin.
the upper limits of normal. Median progression-free and overall survival for the entire cohort was 2.4 and 5.2 months, respectively, with a 6-month survival rate of 42.5%.

Based on this signal of activity, a global Phase III, randomized, open-label trial called NAPOLI-1 (von Hoff et al; updated in Chen et al) was designed to formally evaluate the efficacy of nal-IRI for patients with metastatic pancreatic cancer previously treated with a gemcitabine-based regimen (one or more prior lines of therapy allowed). The study was originally intended to provide a direct head-to-head comparison between two arms: nal-IRI at the same dose schedule used in the Phase II trial (120 mg/m² every 3 weeks), and a control arm of 5-FU (administered as a 24-hour infusion at 2,000 mg/m²) plus LV (200 mg/m²), administered weekly for 4 out of 6 weeks. However, shortly after the study began enrollment, results of the PEPCOL colorectal trial became available suggesting a favorable safety profile of biweekly nal-IRI plus infusional 5-FU and LV; on this basis, the trial design was modified to include a third arm consisting of the combination of nal-IRI (80 mg/m²), 46-hour infusion of 5-fluorouracil (2,400 mg/m²), and LV (400 mg/m²), administered in 2-week cycles. In total, 417 patients were enrolled across the three treatment arms.

The main safety and efficacy findings of NAPOLI-1 are summarized in Table 4. Gastrointestinal-related toxicities, including nausea, vomiting, and diarrhea, were the most common adverse events reported, and occurred more frequently in the two nal-IRI-containing arms compared to the 5-FU/LV alone arm (with the highest incidence observed in the nal-IRI monotherapy arm). The majority of these were grades 1 and 2, although grade 3 or 4 diarrhea was reported in 21% of patients receiving nal-IRI alone and 13% in those receiving nal-IRI plus 5-FU/LV. Complications of neutropenia (neutropenic sepsis, febrile neutropenia) occurred in less than 5% of patients on either nal-IRI-containing arm, vs no reported cases on the 5-FU/LV alone arm. In total, five deaths attributed to study treatment were reported, four in the nal-IRI arm (gastrointestinal toxicity, infectious enterocolitis, septic shock, and disseminated intravascular coagulation with pulmonary embolism) and one in the nal-IRI plus 5-FU/LV arm (septic shock).

In the entire (intention-to-treat) cohort, patients on the nal-IRI plus 5-FU/LV arm demonstrated statistically significant improvements compared with those on the 5-FU/LV alone arm in terms of all clinical relevant parameters, as shown in Table 3. Hazard ratios for median OS, PFS, and time to treatment failure were 0.67, 0.56, and 0.6, respectively, all statistically significant. Significantly higher rates of objective radiographic response and CA19-9 decline ≥50% were also observed. Meanwhile, while nal-IRI alone also produced significantly higher rates of radiographic and biomarker response compared to 5-FU/LV, overall and progression-free survival rates were not significantly higher (HR for OS and PFS =0.99 and 0.81, respectively). Forest plot analyses showed that survival benefit for the MM-398-containing combination was maintained across all subgroups, including those with lower Karnofsky performance status (KPS 70–80), age greater than 65 years old, and receiving two or more prior lines of systemic therapy.

On the basis of these positive results, the FDA in October 2015 approved nal-IRI in combination with 5-FU/LV for the treatment of patients with metastatic pancreatic cancer following disease progression on gemcitabine-based therapy. This represented a landmark of sorts, as it became

---

**Table 4 Safety and efficacy results of the Phase III NAPOLI-1 trial**

<table>
<thead>
<tr>
<th>Adverse event (%)</th>
<th>nal-IRI +5-FU/LV (n=117)</th>
<th>5-FU/LV (n=149)</th>
<th>nal-IRI (n=151)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Any grade</td>
<td>Grade 3/4</td>
<td>Any grade</td>
</tr>
<tr>
<td>Safety</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diarrhea</td>
<td>59</td>
<td>13</td>
<td>26</td>
</tr>
<tr>
<td>Vomiting</td>
<td>52</td>
<td>11</td>
<td>26</td>
</tr>
<tr>
<td>Nausea</td>
<td>51</td>
<td>8</td>
<td>34</td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>44</td>
<td>4</td>
<td>32</td>
</tr>
<tr>
<td>Fatigue</td>
<td>40</td>
<td>14</td>
<td>28</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>39</td>
<td>27</td>
<td>5</td>
</tr>
<tr>
<td>Efficacy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median overall survival (months)</td>
<td>6.1</td>
<td></td>
<td>4.2</td>
</tr>
<tr>
<td>Median progression-free survival (months)</td>
<td>3.1</td>
<td></td>
<td>1.5</td>
</tr>
<tr>
<td>Median time to treatment failure (months)</td>
<td>2.3</td>
<td></td>
<td>1.4</td>
</tr>
<tr>
<td>Objective response rate (%)</td>
<td>16</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>CA19-9 reduction ≥50% (%)</td>
<td>29</td>
<td></td>
<td>10</td>
</tr>
</tbody>
</table>

**Notes:** Data from von Hoff D, Dhindsa N, Bayever E, et al.64, Chen L, Von Hoff D, Li C, et al.67

**Abbreviations:** nal-IRI, nanoliposomal irinotecan; 5-FU, 5-fluorouracil; LV, leucovorin; CA19-9, carbohydrate antigen 19-9.
the first therapeutic agent to receive approval in this disease specifically for use in the second-line setting and beyond.

Future directions

The approval of nal-IRI raises a number of practical issues as well as considerations that may inform future clinical trial design. First of all, selection of the individuals most likely to benefit from, and tolerate, nal-IRI requires further clarification and refinement. The FDA-approved indication specifies this drug should be limited to those patients who have received prior gemcitabine-based treatment; at present, this would most commonly consist of the combination of gemcitabine and nab-paclitaxel, or less commonly another gemcitabine-based doublet or monotherapy. On the other hand, whether nal-IRI plus 5-FU/LV has any activity following first-line treatment with FOLFIRINOX, the other first-line standard for metastatic pancreatic cancer, is unknown; to date, we have no knowledge regarding whether the superior biodistribution and pharmacokinetic properties of nal-IRI can overcome resistance to a standard irinotecan-containing regimen. This highlights a related question: how does nal-IRI compare to standard irinotecan in pancreatic cancer? It seems unlikely that a randomized clinical trial directly comparing FOLFIRI to nal-IRI plus 5-FU/LV will ever be performed, and so we are left using historic FOLFIRI data from relatively small patient cohorts to make (admittedly inexact) cross-study comparisons regarding their respective efficacies in this disease setting.

Furthermore, does the nal-IRI-based combination now supplant the prior de facto second-line standard of care, FOLFOX, for the treatment of metastatic pancreatic cancer? Again, a head-to-head comparison of these two regimens has not been formally performed. One might conceivably develop a biomarker- or pharmacogenetically-driven approach to guide selection of therapy (eg, to choose between an irinotecan- vs platinum-based regimen). It is well-known, for instance, that genetic variants in isoforms of the enzyme UDP-glucuronosyltransferase, in particular UGT1A1, contribute to variability in the metabolism and excretion of irinotecan, producing significant interpatient differences in drug-related toxicity. The most common example of this is UGT1A1*28; individuals who are homozygous for this allele (also known as 7/7, based on the number of repeats of the two-base insertion TA in the promoter region of the gene), which is associated with severely reduced enzymatic activity, are more than threefold likely to develop severe neutropenia following irinotecan-based therapy compared to those with wild genotype (reviewed in Palomaki et al[48]). While relatively scant pharmacogenetic data are available from prior nal-IRI studies to provide guidance, it would be reasonable to use UGT1A1 genotyping to help in this decision-making process. For example, those individuals harboring genetic polymorphisms known to confer greater toxicity might proceed with nal-IRI at reduced starting doses, or even steer away from this agent, if they are particularly fragile and the risk of major toxicity is too high.

Certainly the other area ripe for consideration in future studies centers on the feasibility of combining nal-IRI with other drugs; this could entail either combinations with other cytotoxic agents, or using nal-IRI (±5-FU/LV) as a chemotherapy backbone upon which to add molecularly targeted agents or immunotherapies. Of particular interest is evaluation of nal-IRI in the frontline setting, most notably as part of an FOLFIRINOX regimen where nal-IRI is substituted for standard irinotecan. An ongoing clinical trial that recently opened in September 2015 is looking at this particular combination in newly diagnosed patients with metastatic disease (NCT02551991). Following a safety run-in to confirm the proper dosing and tolerability of nal-IRI in combination with oxaliplatin and 5-FU/LV, the study will then randomize patients to one of three arms: this triple-drug combination regimen, nal-IRI plus 5-FU/LV, or the combination of gemcitabine plus nab-paclitaxel.

Conclusion

In summary, nal-IRI is an important advance in the treatment landscape for metastatic pancreatic cancer. Not only does it represent the first drug specifically approved for use in the second-line setting and beyond in this disease, but nal-IRI also serves as an important proof of principle as the first liposomal formulation of an anticancer agent to gain an indication for any gastrointestinal malignancy. Taking advantage of its ability to deliver an increased drug payload to sites of disease, without concomitant increased systemic toxicity, nal-IRI offers several pharmacologic advantages over free irinotecan. Whether this success ushers in a new era of exploration of liposomal anticancer drugs, or other efficient delivery vehicles, remains to be seen. Successor studies will be critical not only to further define the appropriate use of nal-IRI in pancreatic and other camptothecin-sensitive malignancies, but also to explore predictive biomarkers of drug sensitivity as well as the pharmacodynamics effects of nal-IRI on the tumor and its microenvironment (which could be readily evaluated, for example, in the neoadjuvant setting). For now, from a practical perspective, nal-IRI represents a valuable step in allowing more patients with
metastatic pancreatic cancer to be sequenced through two, or even more, lines of systemic therapy with the promise of clinically meaningful improvements in longevity.

**Disclosure**

The author has previously participated in several advisory board meetings for Merrimack. PharmaEngine provided financial support to his institution for conduct of the Phase II trial of nal-IRI in pancreatic cancer. The author reports no other conflicts of interest in this work.

**References**


